A diagnostic host response biosignature for COVID-19 from RNA profiling of nasal swabs and blood
Por:
Ng D.L., Granados A.C., Santos Y.A., Servellita V., Goldgof G.M., Meydan C., Sotomayor-Gonzalez A., Levine A.G., Balcerek J., Han L.M., Akagi N., Truong K., Neumann N.M., Nguyen D.N., Bapat S.P., Cheng J., Martin C.S.-S., Federman S., Foox J., Gopez A., Li T., Chan R., Chu C.S., Wabl C.A., Gliwa A.S., Reyes K., Pan C.-Y., Guevara H., Wadford D., Miller S., Mason C.E., Chiu C.Y.
Publicada:
1 ene 2021
Categoría:
Multidisciplinary
Resumen:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease-19 (COVID-19), has emerged as the cause of a global pandemic. We used RNA sequencing to analyze 286 nasopharyngeal (NP) swab and 53 whole-blood (WB) samples from 333 patients with COVID-19 and controls. Overall, a muted immune response was observed in COVID-19 relative to other infections (influenza, other seasonal coronaviruses, and bacterial sepsis), with paradoxical down-regulation of several key differentially expressed genes. Hospitalized patients and outpatients exhibited up-regulation of interferon-associated pathways, although heightened and more robust inflammatory responses were observed in hospitalized patients with more clinically severe illness. Two-layer machine learning-based host classifiers consisting of complete (>1000 genes), medium (<100), and small (<20) gene biomarker panels identified COVID-19 disease with 85.1-86.5% accuracy when benchmarked using an independent test set. SARS-CoV-2 infection has a distinct biosignature that differs between NP swabs and WB and can be leveraged for COVID-19 diagnosis. Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).
Filiaciones:
Department of Pathology, University of California, San Francisco, San Francisco, CA, United States
Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, United States
UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, United States
Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, United States
HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, United States
WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine, New York, NY, United States
Diabetes Center, University of California, San Francisco, San Francisco, CA, United States
Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, San Francisco, CA, United States
Department of Preventive and Restorative Dental Sciences, University of California, San Francisco, San Francisco, CA, United States
Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, United States
Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA, United States
Viral and Rickettsial Disease Laboratory, California Department of Health, Richmond, CA, United States
New York Genome Center, New York, NY, United States
Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, United States
All Open Access; Green
|